A Phase II, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Japanese Patients Who Have Systemic Lupus Erythematosus (SLE).

Trial Profile

A Phase II, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Japanese Patients Who Have Systemic Lupus Erythematosus (SLE).

Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2017

At a glance

  • Drugs Sifalimumab (Primary) ; Sifalimumab
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 19 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 17 Oct 2015 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016 as reported by the ClinicalTrials.gov record.
    • 25 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top